Although the National Asthma Education and Prevention Program's (NAEPP) guidelines for managing asthma have been widely disseminated, compliance has been less than impressive. Results of a study by Grant and associates in the Chicago area reveal a considerable discrepancy between the NAEPP's therapeutic goals and the asthma control level achieved.
Although the National Asthma Education and Prevention Program's (NAEPP) guidelines for managing asthma have been widely disseminated, compliance has been less than impressive. Results of a study by Grant and associates in the Chicago area reveal a considerable discrepancy between the NAEPP's therapeutic goals and the asthma control level achieved.
They conducted a telephone survey that included 152 adults and children who had active asthma. The incidences of asthma-related emergency department (ED) visits and hospitalizations were 25.7% and 6.6%, respectively.
African American participants were 6.3 times more likely to have visited the ED and 12.3 times more likely to have been hospitalized; these differences could not be attributed solely to asthma prevalence demographics. The results also highlighted the need for improvement in key interventions, such as inhaler-technique education, particularly in patients from low-income households.
In a related editorial, Foggs noted that in Chicago to date, there is a glaring discrepancy between the level of asthma control that is possible (based on available therapies) and the actual level of asthma control (based on resource utilization and morbidity), especially in African American and lower-income communities.
He added that access to health care and continuity of treatment may no longer be the primary obstacles. African American patients who have health insurance are less likely to receive medication or a high level of care than are other populations. Foggs concluded that initiatives to eliminate racial disparities in asthma care must be vigorously pursued.
Kymera's Oral STAT6 Degrader KT-621 Shows Biologic-Like Activity in Early Atopic Dermatitis Trial
December 8th 2025KT-621 achieved deep STAT6 degradation and strong 4-week EASI and itch reductions, offering a potential new oral option for moderate–severe AD and other Th2 inflammation-driven disease.